Xenetic Biosciences, Inc.
(NASDAQ : XBIO)

( )
XBIO After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
-0.26%203.421.3%$752.26m
GILDGilead Sciences, Inc.
0.14%64.220.9%$374.75m
CELGCelgene Corporation
0.03%95.711.3%$325.97m
ALXNAlexion Pharmaceuticals, Inc.
7.53%123.492.0%$306.94m
ILMNIllumina, Inc.
-0.66%288.583.5%$277.12m
BIIBBiogen Inc.
-0.48%232.061.3%$268.05m
VRTXVertex Pharmaceuticals Incorporated
-1.16%184.241.9%$256.63m
EXASExact Sciences Corporation
-1.14%117.8724.1%$239.89m
REGNRegeneron Pharmaceuticals, Inc.
-0.93%295.022.6%$203.40m
AAgilent Technologies, Inc.
-0.69%71.701.6%$193.78m
SRPTSarepta Therapeutics, Inc.
-6.34%95.0714.7%$184.59m
BMRNBioMarin Pharmaceutical Inc.
-1.05%77.404.3%$97.47m
INCYIncyte Corporation
-0.59%85.562.5%$96.06m
GHDXGenomic Health, Inc.
-1.12%73.521.8%$85.99m
SGENSeattle Genetics, Inc.
-2.01%78.366.5%$79.57m

Company Profile

Xenetic Biosciences, Inc. engages in the discovery, research, and development of next generation biologic drugs and novel orphan oncology therapeutics. Its lead investigational product candidate is oncology therapeutic XBIO-101 (sodium cridanimod), which focuses on the treatment of progesterone resistant endometrial cancer. It also offers proprietary drug development platform, PolyXen, which enables next-generation biologic drugs by improving their half-life and other pharmacological properties. The company was founded on August 9, 2011 and is headquartered in Framingham, MA.